In the cfDNA analysis of this study, all paired FNA samples were derived from advanced pancreatic cancers with KRAS mutations; the detection rate of KRAS mutations in cfDNA by ddPCR was not very high (49%). This evidence concerns the gene KRAS and familial pancreatic carcinoma.